Recent Updates
Recently added Catalysts

moxidectin

Phase 1

Infection | Small molecule | Other |Pfizer, Inc.|Last Updated: Feb 15, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLEDBiomarker
Total Trials2
Total Enrollment66
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00736697Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of MoxidectinPHASE1 COMPLETED 54Nov 1, 2008May 1, 2009Feb 15, 20111 France
NCT00751764Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding WomenPHASE1 COMPLETED 12Nov 1, 2008Sep 1, 2009Sep 16, 20101 United Kingdom
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Blood samples
4 months
Secondary Endpoints
Electrocardiograms
4 months
Safety based on adverse event monitoring, vital sign measurements, 12-lead ECGs and routine lab tests.
4 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
Treatment Arms
ArmTypeDescription
1EXPERIMENTAL -
Interventions
NameTypeDescription
moxidectinDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria * Men or women of non childbearing potential aged 18 to 50 years inclusive at screening. * Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight greater than or equal to 50 kg. Exclusion criteria * Any clinical important deviation from normal limits in physic...

Countries:FranceUnited Kingdom
Unlock Eligibility Criteria